are predicted at the 3# end of the SARS-CoV genome (ORFs 3a, 3b, 7a, 7b, 8ab, and 9b) (Snijder et al., 2003). cessory genes" have proven dispensable for coronavirus viability in vitro, although their deletion often and Molecular Biophysics Washington University School of Medicine leads to viral attenuation in vivo (de Haan et al., 2002). These genes are therefore particularly interesting, con-660 South Euclid Avenue St. Louis, Missouri 63110 sidering that nonessential accessory genes from a wide array of viruses function to circumvent host innate and adaptive immune responses (Alcami and Koszinowski, 2000; Ploegh, 1998). Summary In this study, we examine the product of the SARS-CoV accessory gene ORF 7a (Snijder et al., 2003) (also The open reading frame (ORF) 7a of the SARS-associknown as ORF 8 or X4) (Marra et al., 2003; Rota et al., ated coronavirus (SARS-CoV) encodes a unique type 2003). Sequence analysis predicts that ORF 7a en-I transmembrane protein of unknown function. We codes a type I transmembrane protein, 122 amino acids have determined the 1.8 Å resolution crystal structure in length, consisting of a 15 residue N-terminal signal of the N-terminal ectodomain of orf7a, revealing a peptide, an 81 residue luminal domain, a 21 residue compact seven-stranded ␤ sandwich unexpectedly
compactly folded monomer. We verified the identity of most favored region of the Ramachandran plot and the remaining 5.2% in the additionally allowed region as the orf7a ectodomain fragment by electrospray mass defined by PROCHECK (Laskowski et al., 1993) . There spectrometry (see Experimental Procedures). The obare no residues in the disallowed or generously allowed served mass is consistent with two disulfide bonds in regions. The final model has an R work of 22.3% to 1.8 Å the refolded molecule. The protein runs as a single speresolution, with an R free of 27.5%. cies on native PAGE and is stable in solution at 10 mg/ Our model for the orf7a luminal domain consists of ml over a period of several weeks. seven β strands which form two β sheets, compactly arranged in an Ig-like β sandwich fold ( Figure 1B) . How-Structure of the Orf7a Luminal Domain ever, the precise topology of orf7a is distinctive from We next initiated a structural-genomics-type examinathat of typical Ig-superfamily members ( Figure 1C ). tion of orf7a. We hoped to gain insight into the potential Strand A, instead of running antiparallel to strand B, function of orf7a by investigating the structural relationhas switched sheets and lies parallel to strand G. Like ships between orf7a and other well-characterized promany C1-type Ig domains, both the C# and C$ strands teins. Crystallization screening of the refolded orf7a are absent. In addition, the C and D strands are both protein yielded diffraction-quality hexagonal crystals very short: the C strand is only 4 amino acids in length, belonging to space group P3 1 (a = b = 37.10 Å, c = while the D strand is just 3 residues long. The structure 55.33 Å), which grew over a 3 day period in hanging of orf7a also contains two unusual disulfide bonds condrops to an approximate size of 0.2 × 0.1 × 0.1 mm.
necting the BED and AGFC sheets. Neither occurs in Initial phasing was accomplished by multiple isomorthe typical position occupied by the Ig-superfamily caphous replacement (MIR) using data collected from three nonical disulfide (i.e., connecting the B and F strands). different Pt heavy atom derivatives (Table 1 ). The result-
The first disulfide of orf7a connects the end of strand ing electron density maps were readily interpretable A to the E-F loop, while the second disulfide connects ( Figure 1A ). An initial model, spanning residues 1-67 the short B-C and F-G loops. without a main chain break, was obtained directly from We sought to identify proteins of similar topology by experimental phase using the autobuild feature of ARP/ performing a Dali search (Holm and Sander, 1995 with 6% sequence identity) and the N-terminal domain and immunoprecipitation assays (Table 2A ). To prove that the IgG 2b isotype clone 2E11 was specific for na-of the human interleukin-1 receptor (IL-1R) (PDB ID 1IRA, fragment 1-94, rmsd of 2.0 Å for 46 aligned resi-tive orf7a, immunoprecipitation studies were performed using lysate from SARS-CoV-infected cells. Vero cells dues, with 11% sequence identity). Both structures are considered examples of I-set Ig domains as defined by were infected with SARS-CoV at a multiplicity of infection (moi) of 0.01 for 48 hr in accordance with the rules SCOP (Murzin et al., 1995) . Comparisons of orf7a with 55 additional members of the Ig superfamily identified and regulations of Washington University and the "Laboratory Biosafety Guidelines for Handling and Process-by Dali revealed sequence identities ranging from 2% to 16% for aligned core residues, consistent with our ing Specimens Associated with SARS-CoV" as put forward by the Department of Health and Human Services failure to predict an Ig-like fold from the primary sequence alone. Also, compared with most Ig folds, the Centers for Disease Control and Prevention (CDC). All manipulation of infectious samples took place in a BSL-3 orf7a luminal domain is extremely small, consisting of only 65 amino acids. For comparison, the average biological safety facility. The infected cells were washed, solubilized in 1.0% Triton X-100, and immune com-length of an I-set domain in HOMSTRAD (Mizuguchi et al., 1998) is 98 amino acids. In addition to the short C plexes were recovered on protein A Sepharose. As expected, the 2E11 clone immunoprecipitated a single and D strands, the membrane-distal B-C and F-G loops are also comparatively short. These differences are band of w12 kDa. This protein was identified as orf7a by N-terminal sequencing (Table 2B ). An identical se-best seen in the structure-based alignment of the I-set domains with orf7a ( Figure 1D ). quence was obtained using lysate from 293T cells transfected with an orf7a cDNA. In both cases, the predicted 15 amino acid signal peptide (MKIILFLTLIVFTSC)
Localization of Orf7a in SARS-CoV-Infected Cells
In order to characterize the expression and intracellular of orf7a had been removed, presumably by signal peptidase cleavage. These results and the inability of 2E11 trafficking of orf7a, we generated monoclonal antibodies (mAbs) specific for the luminal domain. Recombi-to recognize denatured (boiled-reduced) recombinant orf7a protein on Western blot support the conclusion nant soluble-refolded orf7a protein was used to immunize mice. Solid-phase ELISA identified 24 hybridomas that 2E11 is specific for orf7a in its natively expressed form. The ability of the conformation-dependent 2E11 producing mAb specific for the refolded protein. These were characterized in cell staining, Western blotting, mAb (raised against recombinant, refolded orf7a) to im- tively charged residues proximal to the membrane (Lys103, Arg104, and Lys105 in Figure 1D )
. This triplet sequence ([Arg/Lys][X][Arg/Lys]) has been found in sev-Localization Studies of Orf7a in Cell Transfectants

Vero cells transfected with an ORF 7a cDNA showed a eral Golgi resident proteins and appears to be required for recognition by the COPII vesicular system impli-similar pattern; intact cells displayed little surface orf7a staining, while permeabilized cells displayed intense in-cated in the transport of proteins from ER to Golgi compartments (Giraudo and Maccioni, 2003; Bickford et al., tracellular staining (Figures 2G and 2H). From this result, we conclude that orf7a does not require the expression 2004). To examine the role of the orf7a cytoplasmic tail, we constructed a mutant orf7a-GFP fusion in which the of other viral proteins for its intracellular trafficking and retention. To facilitate analysis of the intracellular distri-
two Lys tail residues were changed to Ala. The orf7a-AA-GFP tail mutant, like the wild-type, displayed only bution, a green fluorescence protein (GFP) tag was fused in-frame to the carboxyl terminus. The fluores-a low level of expression at the plasma membrane of transfected cells ( Figure 3A , lower panels). The majority cent pattern was clearly distinct from GFP alone ( Figure  2K ). The fusion tag also did not alter the observed intra-of the mutant protein colocalized with antibodies directed against the ER resident protein calnexin ( 
Vero cells were either mock infected ([A], [C], and [E]) or infected with SARS-CoV ([B], [D], and [F]) for 18 hr at an moi of 5. As expected, the spike protein was clearly present at the surface of the SARS-CoV-infected but not mock-infected cells ([A] and [B]). Incubation with the anti-orf7a monoclonal antibody 2E11 demonstrated only limited cell-surface expression of orf7a. An intracellular pool of orf7a was clearly evident after saponin permeabilization ([E] and [F]). The anti-SARS antibody is a mixture of hybridoma supernatants specific for SARS proteins and found to primarily recognize the S protein by Western blotting (a gift of Larry Anderson, CDC). Intracellular retention of orf7a does not require other viral proteins. When an orf7a cDNA is used to transiently transfect 293T cells, very little orf7a can be detected at the cell surface using 2E11 (G). Again, saponin pretreatment allowed staining of the intracellular orf7a (H). Addition of a C-terminal GFP tag did not significantly alter this intracellular distribution. A good colocalization was observed between orf7a staining (red) and GFP fluorescence (green) in this transfectant ([I] and [J]
). The orf7a-GFP distribution was distinct from that seen for GFP alone (K). marker protein retained in the Golgi, as seen by com-perfamily. This common structural fold occurs in a wide variety of proteins, where it performs a diverse set of paring the colocalization of this chimeric construct with Golgin 97 ( Figure 4B ). However, localization of the CD4/ functions. For example, the fold is found in proteins of the extracellular matrix, muscle proteins, proteins of the orf7a TM tail construct was not as tight as that seen for orf7a alone, suggesting that residues in the orf7a 
If SARS-CoV buds into the ERGIC as other coronaviruses do, then our data indicate that orf7a traffics through the budding compartment. It is conceivable that orf7a may play a role in viral assembly or budding events unique to SARS-CoV. In support of this idea, Tan et al. have presented coimmunoprecipitation data suggesting an interaction between orf7a and the product of another SARS-CoV accessory gene, ORF3a, a protein which in turn interacts with the structural proteins M, E, and S (Tan et al., 2004). Alternatively, orf7a may itself be packaged into virions, possibly to serve as a secondary attachment protein in a manner analogous to HE. So far, studies aimed at identifying the structural proteins of the SARS-CoV virion have failed to detect orf7a (Krokhin et al., 2003; Ying et al., 2004), although it is worth noting that these methods also have failed to detect the virion-associated E protein. We tested whether our anti-orf7a monoclonal antibodies could block the production of virus or its cytopathic effects in SARS-CoV-infected Vero cells. However, no neutralization effect was observed (data not shown).
What other functions could orf7a serve within the context of the ER/Golgi network? A significant number of viral accessory proteins have been found to be critical for the evasion of host-mediated immunity, interfering with diverse processes, including apoptosis, complement activation, cytokine signaling, and innate and adaptive immune surveillance (Alcami and Koszinowski, 2000; Ploegh, 1998) . While many of these proteins act at the plasma membrane or are secreted from infected cells, others have been found to operate within methanol were required to destain the blot. The orf7a region was excised for N-terminal sequencing (Table 2B) . 
Crystal Growth and Preparation
